Ada Braun

4.4k citations

63 papers · 3.2k indexed · 2 hit papers · h-index 22

Impact in

Oncology top 1%
- Bone health and treatments
- Cancer Diagnosis and Treatment
Orthopedics and Sports Medicine top 0.5%
- Bone and Joint Diseases

Papers in ⓘ

Oncology 55
- Bone health and treatments 47
- Cancer Diagnosis and Treatment 12
- Cancer Treatment and Pharmacology 6
Radiology, Nuclear Medicine and Imaging 25
- Radiopharmaceutical Chemistry and Applications 22

Co-authors: Alison Stopeck (22 shared papers)Allan Lipton (16 shared papers)Denise A. Yardley (9 shared papers)María Eugenia Ibarrarán Viniegra (6 shared papers)Roger Dansey (12 shared papers)Susie Jun (4 shared papers)Jean-Jacques Body (7 shared papers)Michelle Fan (10 shared papers)
Journals: Journal of Clinical Oncology (22 papers)Cancer Research (8 papers)European Journal of Cancer (7 papers)Annals of Oncology (6 papers)Supportive Care in Cancer (3 papers)
Partner nations: United States Australia United Kingdom

In The Last Decade

Ada Braun

62 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials 2012 · 420 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 European Journal of Cancer
2010 Journal of Clinical Oncology

Peers

Countries citing papers authored by Ada Braun

Since Specialization

Citations

This map shows the geographic impact of Ada Braun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ada Braun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ada Braun more than expected).

Fields of papers citing papers by Ada Braun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ada Braun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ada Braun. The network helps show where Ada Braun may publish in the future.

Co-authors

The 25 scholars most cited alongside Ada Braun, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ada Braun Line = papers co-authored together Ada Braun links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 63 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study Journal of Clinical Oncology ·Alison Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard H. De Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise A. Yardley, María Eugenia Ibarrarán Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun, Ada Braun Hit paper breakdown →	2010	1102
2	Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials European Journal of Cancer ·Allan Lipton, Karim Fizazi, Alison Stopeck, David H. Henry, Janet E. Brown, Denise A. Yardley, Gary Richardson, Salvatore Siena, Pablo Maroto, Michael Clemens, Boris Bilynskyy, Veena Charu, Philippe Beuzeboc, Michael Rader, María Eugenia Ibarrarán Viniegra, Fred Saad, Chunlei Ke, Ada Braun, Susie Jun Hit paper breakdown →	2012	420
3	Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor Journal of Clinical Oncology ·U. Vanhoefer, Mitra Tewes, Federico Rojo, Olaf Dirsch, N. Schleucher, Oliver Rosen, J. Tillner, Andreas Kovar, Ada Braun, Tanja Trarbach, S. Seeber, A. Harstrick, José Baselga	2003	221
4	Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer Supportive Care in Cancer ·Alison Stopeck, Karim Fizazi, Jean-Jacques Body, Janet E. Brown, Michael A. Carducci, Ingo Diel, Yasuhiro Fujiwara, Miguel Martín, Alexander Paterson, Katia Tonkin, Neal D. Shore, Paul Sieber, Frank Kueppers, Lawrence I. Karsh, Denise A. Yardley, Huei Wang, Tapan Maniar, Jorge Arellano, Ada Braun	2015	136
5	Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events Annals of Oncology ·Mitchell R. Smith, Robert E. Coleman, Laurence Klotz, K. Pittman, Piotr Milecki, Siobhan Ng, K.N. Chi, Arun Balakumaran, R. Wei, H. Wang, Ada Braun, Karim Fizazi	2014	117
6	Denosumab for Treatment of Hypercalcemia of Malignancy The Journal of Clinical Endocrinology & Metabolism ·Mimi I. Hu, Ilya Glezerman, Sophie Leboulleux, Karl Insogna, Rasim Gucalp, Waldemar Misiorowski, Bennett W. Yu, Paul Zorsky, Diégo Tosi, Alberto Bessudo, Arnaud Jaccard, Giuseppe Tonini, Wendy Ying, Ada Braun, Rajul K. Jain	2014	106
7	Hypocalcaemia in patients with metastatic bone disease treated with denosumab European Journal of Cancer ·Jean-Jacques Body, Henry G. Bone, Richard H. De Boer, Alison Stopeck, Catherine Van Poznak, Ronaldo Damião, Karim Fizazi, David H. Henry, Toni Ibrahim, Allan Lipton, Fred Saad, Neal D. Shore, Toshimi Takano, Adam J. Shaywitz, Huei Wang, Oswaldo L. Bracco, Ada Braun, Paul J. Kostenuik	2015	103
8	Pain outcomes in patients with advanced breast cancer and bone metastases Cancer ·Charles S. Cleeland, Jean‐Jacques Body, Alison Stopeck, Roger von Moos, Lesley Fallowfield, Susan D. Mathias, Donald L. Patrick, Mark Clemons, Katia Tonkin, Norikazu Masuda, Allan Lipton, Richard de Boer, Stefania Salvagni, Célia Tosello Oliveira, Yi Qian, Qi Jiang, Roger Dansey, Ada Braun, Karen Chung	2012	100
9	Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid Clinical Cancer Research ·Miguel Martín, Richard H. Bell, Hugues Bourgeois, Adam Brufsky, Ingo Diel, Alexandru Eniu, Lesley Fallowfield, Yasuhiro Fujiwara, Jacek Jassem, Alexander Paterson, Diana Ritchie, Günther Steger, Alison Stopeck, Charles L. Vogel, Michelle Fan, Qi Jiang, Karen Chung, Roger Dansey, Ada Braun	2012	96
10	Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics European Journal of Cancer ·Allan Lipton, Karim Fizazi, Alison Stopeck, David H. Henry, Mitchell R. Smith, Neal D. Shore, Miguel Martín, Saroj Vadhan‐Raj, Janet E. Brown, Gary Richardson, Fred Saad, Denise A. Yardley, Kefei Zhou, Arun Balakumaran, Ada Braun	2015	83
11	Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid Supportive Care in Cancer ·Roger von Moos, Jean-Jacques Body, Blair Egerdie, Alison Stopeck, Janet E. Brown, Danail Damyanov, Lesley Fallowfield, Gavin Marx, Charles S. Cleeland, Donald L. Patrick, Felipe Palazzo, Yi Qian, Ada Braun, Karen Chung	2013	68
12	Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases Supportive Care in Cancer ·Roger von Moos, Jean-Jacques Body, Blair Egerdie, Alison Stopeck, Janet E. Brown, Lesley Fallowfield, Donald L. Patrick, Charles S. Cleeland, Danail Damyanov, Felipe Salvador Palazzo, Gavin Marx, Ying Zhou, Ada Braun, Arun Balakumaran, Yi Qian	2015	65
13	New systemic frontline treatment for metastatic colorectal carcinoma Cancer ·Ada Braun, W. Achterrath, H. Wilke, U. Vanhoefer, A. Harstrick, P. Preusser	2004	63
14	2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study European Journal of Cancer Supplements ·Alison Stopeck, J.J. Body, Yasuyuki Fujiwara, Allan Lipton, Guenther G. Steger, María Eugenia Ibarrarán Viniegra, Michelle Fan, Ada Braun, Roger Dansey, Jun Sakata	2009	63
15	Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study Acta Oncologica ·Javier Martín‐Broto, Charles S. Cleeland, Paul Glare, Jacob Engellau, Keith M. Skubitz, Ronald H. Blum, Kristin N. Ganjoo, Arthur P. Staddon, Martin Dominkus, Amy Feng, Yi Qian, Ada Braun, Ira Jacobs, Karen Chung, C. Atchison	2014	54
16	Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial Blood Cancer Journal ·Noopur Raje, Saroj Vadhan‐Raj, Wolfgang Willenbacher, Evangelos Terpos, Vânia Hungria, Andrew Spencer, Yulia Alexeeva, Thierry Façon, A. Keith Stewart, A. Feng, Ada Braun, Arun Balakumaran, G. David Roodman	2016	41
17	Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone World Journal of Surgical Oncology ·Jacob Engellau, Leanne L. Seeger, R. J. Grimer, Robert M. Henshaw, Hans Gelderblom, Edwin Choy, Sant P. Chawla, Peter Reichardt, Michael O’Neal, Amy Feng, Ira Jacobs, Zachary Roberts, Ada Braun, Bruce Allen Bach	2018	39
18	The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease European Journal of Cancer ·Ingo Diel, Jean‐Jacques Body, Alison Stopeck, Saroj Vadhan‐Raj, Andrew Spencer, Günther Steger, Roger von Moos, François Goldwasser, Amy Feng, Ada Braun	2015	34
19	Assessing Analgesic Use in Patients with Advanced Cancer: Development of a New Scale-The Analgesic Quantification Algorithm Pain Medicine ·Karen Chung, Arie Barlev, Ada Braun, Yi Qian, Martin Zagari	2014	32
20	The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction Annals of the New York Academy of Sciences ·Carsten Goessl, Leonid Katz, William C. Dougall, Paul J. Kostenuik, Holly Brenza Zoog, Ada Braun, Roger Dansey, Rachel B. Wagman	2012	30

About Ada Braun

Ada Braun is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Orthopedics and Sports Medicine, Pulmonary and Respiratory Medicine and Biotechnology, having authored 63 papers that have together received 3.2k indexed citations. Recurring topics across this work include Bone health and treatments (47 papers), Radiopharmaceutical Chemistry and Applications (22 papers), Cancer Diagnosis and Treatment (12 papers), Management of metastatic bone disease (11 papers), Prostate Cancer Treatment and Research (9 papers), Medical Imaging and Pathology Studies (7 papers), Bone Metabolism and Diseases (7 papers) and Cancer Treatment and Pharmacology (6 papers). The work is most often cited by research in Oncology (2.7k citations), Orthopedics and Sports Medicine (834 citations), Radiology, Nuclear Medicine and Imaging (749 citations), Pulmonary and Respiratory Medicine (754 citations) and Rheumatology (285 citations). Ada Braun has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Alison Stopeck, Allan Lipton, Denise A. Yardley, María Eugenia Ibarrarán Viniegra, Roger Dansey, Susie Jun, Jean-Jacques Body, Michelle Fan, Katia Tonkin and Yasuhiro Fujiwara. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, European Journal of Cancer, Annals of Oncology and Supportive Care in Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact